Challenges in the management of depressive disorders comorbid with tuberculosis and type 2 diabetes.
Journal
Current opinion in psychiatry
ISSN: 1473-6578
Titre abrégé: Curr Opin Psychiatry
Pays: United States
ID NLM: 8809880
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
4
8
2023
pubmed:
13
7
2023
entrez:
13
7
2023
Statut:
ppublish
Résumé
The aim of this study was to address the most relevant diagnostic and therapeutic challenges in the management of depressive disorders among patients with diabetes mellitus and tuberculosis (TB). Depressive disorder, diabetes mellitus and TB are considered important contributors to the global burden of diseases with an emphasis on developing countries. Depressive disorder increases the chance of negative outcomes during the treatment of both diabetes mellitus and TB, while biological and adaptive changes due to diabetes mellitus and TB increase in turn the chance of depressive disorder. In this review, we present major challenges in the management of depressive disorder among patients with TB and diabetes mellitus, from detection and clinical diagnosis using appropriate diagnostic tools, to selecting the best psychotherapeutic and/or pharmacological intervention, considering the potential, adverse events and interactions due to potential polypharmacy.
Identifiants
pubmed: 37439587
doi: 10.1097/YCO.0000000000000885
pii: 00001504-990000000-00079
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
360-365Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lemogne C, Chauvet-Gelinier J. Depression and the risk of type 2 diabetes. J Psychosom Res 2023; 164:111116.
Chand SP, Arif H. Depression. StatPearls [Internet]. StatPearls Publishing; 2022 [cited 22 February 2023]. https://www.ncbi.nlm.nih.gov/books/NBK430847/ [Accessed 22 February 2023]
Kalinichenko LS, Kornhuber J, Müller CP. The system's genetics of depression and its somatic and mental comorbidities. Transl Neurosci 2022; 13:198–200.
Global Tuberculosis Report 2022 [Internet]. [cited 18 February 2023]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 [Accessed 18 February 2023]
Murray S. Challenges of tuberculosis control. CMAJ 2006; 174:33–34.
Diabetes [Internet]. 2021 [cited 22 February 2023]. https://www.cdc.gov/globalhealth/healthprotection/ncd/diabetes.html
Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: an overview. Avicenna J Med 2020; 10:174–188.
Jarde A, Romano E, Afaq S, et al. Prevalence and risks of tuberculosis multimorbidity in low-income and middle-income countries: a meta-review. BMJ Open 2022; 12:e060906.
Török N, Tanaka M, Vécsei L. Searching for peripheral biomarkers in neurodegenerative diseases: the Tryptophan-Kynurenine metabolic pathway. Int J Mol Sci 2020; 21:9338.
Chandra M, Rana P, Chandra K, Arora VK. Tuberculosis - depression syndemic: a public health challenge. Indian J Tuberc 2019; 66:197–202.
Zhang K, Wang X, Tu J, et al. The interplay between depression and tuberculosis. J Leukoc Biol 2019; 106:749–757.
Joseph JJ, Golden SH. Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus. Ann N Y Acad Sci 2017; 1391:20–34.
Bădescu SV, Tătaru C, Kobylinska L, et al. The association between diabetes mellitus and depression. J Med Life 2016; 9:120–125.
Sartorius N. Depression and diabetes. Dialogues Clin Neurosci 2018; 20:47.
Pence BW, O’Donnell JK, Gaynes BN. The depression treatment cascade in primary care: a public health perspective. Curr Psychiatry Rep 2012; 14:328–335.
Subbaraman R, Nathavitharana RR, Mayer KH, et al. Constructing care cascades for active tuberculosis: a strategy for program monitoring and identifying gaps in quality of care. PLoS Med 2019; 16:e1002754.
Kazemian P, Shebl FM, McCann N, et al. Evaluation of the cascade of diabetes care in the United States, 2005–2016. JAMA Intern Med 2019; 179:1376–1385.
Roy T, Lloyd CE, Pouwer F, et al. Screening tools used for measuring depression among people with Type 1 and Type 2 diabetes: a systematic review. Diabet Med 2012; 29:164–175.
Hermanns N, Caputo S, Dzida G, et al. Screening, evaluation and management of depression in people with diabetes in primary care. Prim Care Diabetes 2013; 7:1–10.
Kalichman SC, Rompa D, Cage M. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV-AIDS. J Nerv Ment Dis 2000; 188:662–670.
Nylen KJ, Williamson JA, O’Hara MW, et al. Validity of somatic symptoms as indicators of depression in pregnancy. Arch Womens Ment Health 2013; 16:203–210.
Taylor R, Lovibond PF, Nicholas MK, et al. The utility of somatic items in the assessment of depression in patients with chronic pain: a comparison of the Zung Self-Rating Depression Scale and the Depression Anxiety Stress Scales in chronic pain and clinical and community samples. Clin J Pain 2005; 21:91–100.
Yonkers KA, Smith MV, Gotman N, Belanger K. Typical somatic symptoms of pregnancy and their impact on a diagnosis of major depressive disorder. Gen Hosp Psychiatry 2009; 31:327–333.
Ugarte-Gil C, Ruiz P, Zamudio C, et al. Association of major depressive episode with negative outcomes of tuberculosis treatment. PLoS One 2013; 8:e69514.
Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. Diabet Med 2014; 31:764–772.
Abdurahman S, Yadeta TA, Ayana DA, et al. Magnitude of depression and associated factors among patients on tuberculosis treatment at public health facilities in Harari Regional State, Eastern Ethiopia: multi-center cross-sectional study. Neuropsychiatr Dis Treat 2022; 18:1405–1419.
Laxmeshwar C, Das M, Mathur T, et al. Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, India. PLoS One 2022; 17:e0263759.
van der Feltz-Cornelis CM, Nuyen J, Stoop C, et al. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. Gen Hosp Psychiatry 2010; 32:380–395.
van der Feltz-Cornelis C, Allen SF, Holt RIG, et al. Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: systematic review and meta-analysis. Brain Behav 2021; 11:e01981.
Palapinyo S, Methaneethorn J, Leelakanok N. Association between polypharmacy and depression: a systematic review and meta-analysis. J Pharm Pract Res 2021; 51:280–299.
Peron EP, Ogbonna KC, Donohoe KL. Antidiabetic medications and polypharmacy. Clin Geriatr Med 2015; 31:17–27. vii.
Tupasi TE, Garfin AMCG, Kurbatova EV, et al. Factors associated with loss to follow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012–2014. Emerg Infect Dis 2016; 22:491–502.
Soedarsono S, Mertaniasih NM, Kusmiati T, et al. Determinant factors for loss to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects. BMC Pulm Med 2021; 21:360.
Bezu H, Seifu D, Yimer G, Mebrhatu T. Prevalence and risk factors of adverse drug reactions associated multidrug resistant tuberculosis treatments in selected treatment centers in Addis Ababa Ethiopia. J Tuberc Res 2014; 02:144–154.
Jacobs TQ, Ross A. Adverse effects profile of multidrug-resistant tuberculosis treatment in a South African outpatient clinic. S Afr Fam Pract 2012; 54:531–539.
Prasad R, Singh A, Gupta N. Adverse drug reactions in tuberculosis and management. Indian J Tuberc 2019; 66:520–532.
May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab 2016; 7:69–83.
Cáceres G, Calderon R, Ugarte-Gil C. Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression. Ther Adv Infect Dis [Internet] 2022; 9:20499361221095831.
Drug Interactions Checker [Internet]. Drugs.com. [cited 4 April 2023].
Filipcić I, Margetić B, Simunović I, Jakovljević M. Depression treatment and its impact upon the quality of life in patients with diabetes type 2 - the Croatian study. Psychiatr Danub 2010; 22:231–235.
Katon WJ, Von Korff M, Lin EHB, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 2004; 61:1042–1049.
Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998; 159:1245–1252.
Oliva V, Lippi M, Paci R, et al. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2021; 109:110266.
Filetti M, Lombardi P, Giusti R, et al. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Cancer Treat Rev 2023; 115:102512.
Cao J, Ouyang Q, Wang S, et al. Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. Invest New Drugs 2020; 38:507–514.
Kinomura M, Iihara H, Fujii H, et al. Effect of mirtazapine for the prevention of nausea and vomiting in patients with thoracic cancer receiving platinum-based chemotherapy. Anticancer Res 2023; 43:1301–1307.
Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71:1259–1272.
Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015; 100:363–370.
Song HR, Woo YS, Wang HR, et al. Does mirtazapine interfere with naturalistic diabetes treatment? J Clin Psychopharmacol 2014; 34:588–594.